Vitrolife AB
STO:VITR
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
156.6
265.6
|
| Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Vitrolife AB
Vitrolife AB
Total Receivables
Vitrolife AB
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Vitrolife AB
STO:VITR
|
Total Receivables
kr708m
|
CAGR 3-Years
44%
|
CAGR 5-Years
23%
|
CAGR 10-Years
25%
|
|
|
Biogaia AB
STO:BIOG B
|
Total Receivables
kr133.9m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
|
|
Bonesupport Holding AB
STO:BONEX
|
Total Receivables
kr224.6m
|
CAGR 3-Years
70%
|
CAGR 5-Years
41%
|
CAGR 10-Years
N/A
|
|
|
Probi AB
STO:PROB
|
Total Receivables
kr114.8m
|
CAGR 3-Years
16%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
17%
|
|
|
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
|
Total Receivables
kr8.1B
|
CAGR 3-Years
27%
|
CAGR 5-Years
24%
|
CAGR 10-Years
29%
|
|
|
BioArctic AB
STO:BIOA B
|
Total Receivables
kr7.1m
|
CAGR 3-Years
8%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
Vitrolife AB
Glance View
Vitrolife AB is a Swedish company that has carved out a significant niche within the biotechnology sector, particularly within reproductive health. Founded in 1994, Vitrolife focuses on the development, production, and commercialization of products designed to optimize fertility treatments. The company’s offerings include a wide range of medical devices and culture media critical for in vitro fertilization (IVF) procedures. These products are used by fertility clinics across the globe, enhancing every stage of assisted reproduction — from egg retrieval and sperm preparation to embryo transfer. This comprehensive approach not only amplifies treatment outcomes but also strengthens Vitrolife's position as a pivotal player in a market where scientific advancement and patient care converge. The company’s business model thrives on a robust combination of research-driven innovation and strategic acquisitions. By continuously refining its product lines and leveraging strategic partnerships with clinics and research institutes, Vitrolife ensures that it remains at the cutting edge of the rapidly evolving fertility landscape. Revenue streams flow in through the sales of these critical fertility products, supported by a well-established distribution network that bridges its Swedish roots with a global customer base. With a commitment to quality and efficacy, Vitrolife makes money by delivering solutions that enhance the success rates of fertility treatments, making the dream of parenthood possible for many around the world.
See Also
What is Vitrolife AB's Total Receivables?
Total Receivables
708m
SEK
Based on the financial report for Sep 30, 2024, Vitrolife AB's Total Receivables amounts to 708m SEK.
What is Vitrolife AB's Total Receivables growth rate?
Total Receivables CAGR 10Y
25%
Over the last year, the Total Receivables growth was 32%. The average annual Total Receivables growth rates for Vitrolife AB have been 44% over the past three years , 23% over the past five years , and 25% over the past ten years .
You don't have any saved screeners yet
